Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Presenilin—Two Heads Better Than One?
17 October 2003. In this week's advanced online edition of PNAS, Raphael Kopan from Washington University School of Medicine, St. Louis, and a host of international collaborators, report that presenilin (PS), the aspartyl protease proposed to be the heart of γ-secretase, may function as a dimer. This may explain how γ-secretase can cleave substrates, such as amyloid-β precursor protein (AβPP) and Notch, in two apparently different locales, the middle and inner edge of the cell membrane.

Joint first authors Eric Schroeter and Ma Xenia Ilagan, tagged PS with two different epitopes to show that the protein dimerizes. Immunoprecipitating these chimeras with an antibody to either epitope also brought down the second chimera. Significantly, this coprecipitation only worked when the differently tagged proteins were expressed in the same hek293 cells, and not when lysates containing single chimeras were mixed. These experiments suggest that the dimers are formed and remain tightly bound in the cell.

The authors suggest that a dimer can explain how PS can catalyze cleavage in the middle and edge of the cell membrane, but emphasize that it may be necessary to have at least three aspartyl residues assembling at the dimer interface to form two catalytic sites. In support of this, Schroeter, Ilagan, and colleagues found that treating cells expressing PS with a photoaffinity label that interacts with the active site led to crosslinking of N-terminal and C-terminal ends of substrate molecules, as would be expected. However, they also found that N-terminal fragments were crosslinked together. The most likely explanation for the latter is that two catalytic sites exist in close proximity to each other.

Other evidence is also presented for a single catalytic site within γ-secretase. The authors found that a range of γ-secretase inhibitors, including MG132, calpeptin, and MD28170, have similar IC50s (the inhibitor concentration necessary to block half of the enzyme activity) for both Notch S3 cleavage (which occurs in the center of the membrane) and Aβ production (which occurs at the inner leaflet of the membrane). Furthermore, when the authors rank the potency of these compounds for inhibiting both cleavages, the orders are the same. And in a classic competition assay for proteolytic activity, Schroeter and Ilagan show that under saturating conditions, Notch and AβPP compete for cleavage, indicating they both sit in the same active site.

A PS dimer goes a long way to explain some of the perplexing observations on γ-secretase, the authors write. For example, with a dimer, allosteric effects may be evoked to explain why some inhibitors (ibuprofen, for one) can shift the preferred AβPP cleavage site to yield Aβ38 instead of Aβ42. Heterozygous dimers may also explain why some of the FAD mutations have partial activity.—Tom Fagan.

Reference:
Schroeter EH, Ilagan MX, Brunkan AL, Hecimovic S, Li YM, Xu M, Lewis HD, Saxena MT, De Strooper B, Coonrod A, Tomita T, Iwatsubo T, Moore CL, Goate A, Wolfe MS, Shearman M, Kopan R. A presenilin dimer at the core of the {gamma}-secretase enzyme: Insights from parallel analysis of Notch 1 and APP proteolysis. Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):13075-13080. Epub 2003 Oct 17. Abstract

 
Comments on News and Primary Papers
  Comment by:  Vincent Marchesi, ARF Advisor
Submitted 21 October 2003  |  Permalink Posted 21 October 2003

These are interesting experiments, but I think we have to be careful about interpreting experimetal results like these too literally. To say that cleavages occur at one "side" of a membrane, or in the "middle", so to speak, give the models that we draw of these complex proteins too much credance, at this stage of our understanding of where and how the abeta peptides are generated. No one yet knows how "intramembranous" proteolytic hydrolysis actually occurs, whether it must necessarily happen within the lipid bilayer,and what happens to the "liberated" intramembranous peptides that allow them to escape into the cytosol. (VT Marchesi)

View all comments by Vincent Marchesi

  Primary Papers: A presenilin dimer at the core of the gamma-secretase enzyme: insights from parallel analysis of Notch 1 and APP proteolysis.

Comment by:  Andre Delacourte, ARF Advisor
Submitted 30 October 2003  |  Permalink Posted 30 October 2003
  I recommend this paper
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad